CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

Once again CHEPLAPHARM proves its M&A competence

Cheplapharm announces the acquisition of two product portfolios from LeoPharma and Takeda

One acquisition, a portfolio of four well established off-patent brands was acquired from LeoPharma. The four products, One-Alpha®, Pimafucin®, Locoid® and Zineryt®, are mainly focused on the therapeutic areas dermatology, gynaecology and bone disorders. With the acquisition Cheplapharm is able to expand its portfolio in Russia, France, Saudi Arabia, UK, Poland and Italy. The active pharmaceutical ingredients (“APIs”) of the products are Alfacalcidol, Hydrocortisone butyrate, Natamycin and Erythromycin together with Zinc Acetate.

The acquisition from Takeda comprises a variety of brands sold predominantly in Europe and Canada. The APIs of the portfolio are: Calcium, Candesartan, Ebrantil and Pioglitazone. The products Vipidin, Calcimagon, Candesartan, Ebrantil and Actos are focused on the therapeutic areas of cardiology and calcium-metabolism and are on sale in more than ten countries. Until the marketing authorizations of all countries have been transferred to CHEPLAPHARM, the production and distribution will be the responsibility by the seller.

“These acquisitions are the first deals with LeoPharma and Takeda, which underpins our constantly growing competence in the acquisition of new products”, said CHEPLAPHARM´s CEO Sebastian F. Braun. “Furthermore, these agreements are matching perfectly with our business strategy to further diversify our product portfolio.”

The purchase price of the first acquisition, made pursuant to an asset purchase agreement signed with LeoPharma on August 28, 2020, amounts to EUR 300m. The second acquisition was signed with Takeda on September 7, 2020, and has a purchase price of EUR 475m. Closing of both acquisitions is expected to be completed by the end of Q4 2020, subject to antitrust approvals and other customary closing conditions.

Edeltraud Lafer, Chief Operating Officer of CHEPLAPHARM concludes: “These recent acquisitions will extend our existing network and are hopefully the first step in a long relationship with the two companies.”

About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe for years.

Please refer to www.cheplapharm.com for additional information.


Investor Relations topics

Back to top expand_less